WPRIM Management System> DCMS> Journal of Gynecologic Oncology> 2015> 26

Volume: 26

1. Platinum sensitivity and non-cross-resistance of cisplatin analogue with cisplatin in recurrent cervical cancer. Page:185—192
2. Role of vaginal pallor reaction in predicting late vaginal stenosis after high-dose-rate brachytherapy in treatment-naive patients with cervical cancer. Page:179—184
3. Cost-effectiveness of para-aortic lymphadenectomy before chemoradiotherapy in locally advanced cervical cancer. Page:171—178
4. Nerve-sparing radical hysterectomy: time for a new standard of care for cervical cancer?. Page:81—82
5. Ovarian cancer risk reduction through opportunistic salpingectomy. Page:83—86
6. FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. Page:87—89
7. Efficacy and oncologic safety of nerve-sparing radical hysterectomy for cervical cancer: a randomized controlled trial. Page:90—99
8. Conventional versus nerve-sparing radical surgery for cervical cancer: a meta-analysis. Page:100—110
9. Low initial human papillomavirus viral load may indicate worse prognosis in patients with cervical carcinoma treated with surgery. Page:111—117
10. Efficacy and tolerability of paclitaxel, ifosfamide, and cisplatin as a neoadjuvant chemotherapy in locally advanced cervical carcinoma. Page:118—124
11. Implications of a two-step procedure in surgical management of patients with early-stage endometrioid endometrial cancer. Page:125—133
12. Hyperthermic intraperitoneal chemotherapy for ovarian cancer: is there a role?. Page:1—2
13. Clinical implication of surgically treated early-stage cervical cancer with multiple high-risk factors. Page:3—11
14. Prognostic factors for patients with cervical cancer treated with concurrent chemoradiotherapy: a retrospective analysis in a Japanese cohort. Page:12—18
15. The incidence of pelvic and para-aortic lymph node metastasis in uterine papillary serous and clear cell carcinoma according to the SEER registry. Page:19—24
16. An analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high volume cancer centers. Page:25—31
17. Risk group criteria for tailoring adjuvant treatment in patients with endometrial cancer: a validation study of the Gynecologic Oncology Group criteria. Page:32—39
18. DNA mismatch repair-related protein loss as a prognostic factor in endometrial cancers. Page:40—45
19. Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings. Page:46—53
20. Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study. Page:54—61
21. Single-site robotic surgery in gynecologic cancer: a pilot study. Page:62—67
22. Asian Society of Gynecologic Oncology International Workshop 2014. Page:68—74
23. Are we ready for conservative treatment in ovarian cancer?. Page:75—76
24. Improving survival after endometrial cancer: the big picture. Page:227—231
25. Robotic high para-aortic lymph node dissection with high port placement using same port for pelvic surgery in gynecologic cancer patients. Page:222—226
26. Surgical staging of para-aortic LN in patients with locally advanced cervix cancer and no evidence of metastases in preoperative PET/CT imaging. Page:352—354
27. Fertility-sparing surgery in high-risk ovarian cancer. Page:350—351
28. Controversies in borderline ovarian tumors. Page:343—349
29. Role of aggressive surgical cytoreduction in advanced ovarian cancer. Page:336—342
30. Identification of high-affinity VEGFR3-binding peptides through a phage-displayed random peptide library. Page:327—335
31. Clinical application of sartorius tendon transposition during radical vulvectomy: a case control study of 58 cases at a single institution. Page:320—326
32. Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer. Page:311—319
33. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients. Page:303—310
34. Synchronous and metachronous malignancy in endometrial cancer patients treated in a tertiary care center of Thailand. Page:293—302
35. Adjuvant sequential chemo and radiotherapy improves the oncological outcome in high risk endometrial cancer. Page:284—292
36. Controversies in the management of endometrial cancer: a survey of the Korean Gynecologic Oncology Group. Page:277—283
37. Pulmonary metastasectomy in uterine malignancy: outcomes and prognostic factors. Page:270—276
38. Longer waiting times for early stage cervical cancer patients undergoing radical hysterectomy are associated with diminished long-term overall survival. Page:262—269
39. Pretreatment risk factors for parametrial involvement in FIGO stage IB1 cervical cancer. Page:255—261
40. A critical assessment on the role of sentinel node mapping in endometrial cancer. Page:252—254
41. Uterine carcinosarcoma/malignant mixed Mullerian tumor incidence is increased in women with breast cancer, but independent of hormone therapy. Page:249—251
42. Wait times from diagnosis to treatment in cancer. Page:246—248
43. Who should be offered non-radical surgery for early-stage cervical cancer?. Page:243—245
44. Personal technical considerations about en bloc pelvic resection. Page:242—242
45. Impact of statins on risk and survival of ovarian cancer. Page:240—241
46. The Korean guideline for cervical cancer screening. Page:232—239
47. Long-term survival of patients with recurrent endometrial stromal sarcoma: a multicenter, observational study. Page:214—221
48. Lymph node metastasis and pattern of recurrence in clinically early stage endometrial cancer with positive lymphovascular space invasion. Page:208—213
49. Transvaginal/transrectal ultrasound for assessing myometrial invasion in endometrial cancer: a comparison of six different approaches. Page:201—207
50. High-dose oral tegafur-uracil maintenance therapy in patients with uterine cervical cancer. Page:193—200
51. The utility of the 3D imaging software in the macroscopic rendering of complex gynecologic specimens. Page:168—169
52. Major clinical research advances in gynecologic cancer in 2014. Page:156—167
53. Surgical technique of en bloc pelvic resection for advanced ovarian cancer. Page:155—155
54. Quality of life and sexuality comparison between sexually active ovarian cancer survivors and healthy women. Page:148—154
55. Physical activity for an ethnically diverse sample of endometrial cancer survivors: a needs assessment and pilot intervention. Page:141—147
56. Prognostic impact of lymphadenectomy in uterine clear cell carcinoma. Page:134—140
57. Staging classification for cancer of the ovary and the fallopian tube should include in situ carcinoma. Page:355—356